[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Pages 47753-47754]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22146]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve expeditious commercialization of 
results of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing. A description of 
the technology follows.

Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis

    The invention pertains to derivatives of 
docosahexaenoylethanolamide (synaptamide or DEA) and their use in 
inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, 
these DEA derivatives can be used as therapeutics for neurodegenerative 
diseases such as traumatic brain injury, spinal cord injury, peripheral 
nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, 
Huntington's disease, Parkinson's disease, amyotrophic lateral 
sclerosis. The DEA derivatives of the invention have increased potency 
and hydrolysis resistance as compared to native DEA. Docosahexaenoic 
acid (DHA), an n-3

[[Page 47754]]

polyunsaturated fatty acid accumulates in the brain during development, 
and has been implicated in learning and memory development. DEA, a 
metabolite derived from DHA, also has been shown to accelerate neuronal 
growth and development. In vitro studies in which neural progenitor 
cells were treated with DEA derivatives showed an increase in the 
number of somatic neurons produced after differentiation.

Potential Commercial Applications

     Neurogenesis,
     Neurite growth,
     Synaptogenesis,
     Therapeutics for traumatic brain injury, spinal cord 
injury, peripheral nerve injury, stroke, multiple sclerosis, autism, 
Alzheimer's disease, Huntington's disease, Parkinson's disease, and 
amyotrophic lateral sclerosis.
    Inventors: Erika Englund (NCATS), Juan Marugan (NCATS), Samarjit 
Patnaik (NCATS), Hee-Yong Kim (NIAAA).
    Intellectual Property: HHS Reference No. E-070-2012/0, U.S. 
Provisional Patent Application 61/624,741 filed April 16, 2012 
(expired), International Patent Application PCT/US2013/032333 filed 
March 15, 2013 (expired), U.S. Patent 9,422,308; German Patent 
602013016154.2, French Patent 2847178, and UK Patent 2847178.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: October 5, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development .
[FR Doc. 2017-22146 Filed 10-12-17; 8:45 am]
 BILLING CODE 4140-01-P